Colinz Laboratories open offer sees only six shares tendered at ₹54

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Only six equity shares were tendered in the open offer for Colinz Laboratories, valuing just ₹324 against a potential ₹3.54 crore.
  • Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar offered ₹54 per share to buy up to 26% of the voting share capital.
  • The open offer was triggered by a pending Share Purchase Agreement for 8,70,500 shares (34.56%) which remains unconsummated.
  • Public shareholding stands at 34.39% post-offer, subject to downward revision upon reclassification of promoter-held shares.
powered bylight_fuzz_icon
50092433

*this image is generated using AI for illustrative purposes only.

The open offer for Colinz Laboratories attracted negligible interest from public shareholders, with only six equity shares tendered during the offer period that ran from August 7 to August 20, 2026.

Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Person Acting in Concert (PAC) Padam Dugar, proposed to acquire up to 6,54,966 fully paid-up equity shares at a price of ₹54 per share. The maximum aggregate consideration for the offer was valued at ₹3,53,68,164, representing 26% of the company’s voting share capital.

Despite the significant size of the mandatory open offer under SEBI (SAST) Regulations, 2011, actual acceptances were minimal. The acquirers accepted the six shares tendered in dematerialized form, resulting in an actual acquisition value of just ₹324.

What the Numbers Show

The divergence between the proposed offer size and actual acceptances highlights a lack of exit interest from existing public shareholders at the offered price. While the acquirers planned to acquire 26% of the voting share capital through the open offer assuming full acceptance, the actual acquisition via this route was negligible. The post-offer shareholding pattern reflects this reality, with the public holding remaining largely unchanged at 34.39% post-offer compared to 49.40% pre-offer, although this figure includes reclassification adjustments.

Shareholding Structure Changes

The acquirers held 3,78,000 shares (15.01%) prior to the public announcement. The open offer was triggered by their agreement to acquire an additional 8,70,500 shares (34.56%) through a Share Purchase Agreement dated June 18, 2026. As of the post-offer advertisement dated September 3, 2026, these transactions had not yet been consummated.

Metric Proposed (Full Acceptance) Actuals
Shares Tendered 6,54,966 6
Offer Price ₹54 ₹54
Aggregate Value ₹3,53,68,164 ₹324
Post-Offer Acquirer Holding 75.57% 49.57%

Upon consummation of the Share Purchase Agreement, the 3,78,000 shares currently classified under the public category will be reclassified to the Promoter/Promoter Group category. This reclassification will further adjust the public holding percentage downwards from the reported 34.39%.

Saffron Capital Advisors Private Limited served as the manager to the open offer, while Bigshare Services Private Limited acted as the registrar. Payment for the accepted shares was made on August 28, 2026.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.01%+4.15%-13.07%+72.74%+68.41%+320.29%

How might the negligible public participation in the open offer impact Colinz Laboratories' future liquidity and trading volume on the stock exchange?

What are the strategic implications for the Dugar family's control over Colinz Laboratories once the pending Share Purchase Agreement is consummated?

Could the low acceptance rate signal underlying concerns among public shareholders regarding the company's valuation or future growth prospects at the ₹54 price point?

Colinz Laboratories schedules 40th AGM for September 22, 2026

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Colinz Laboratories holds its 40th AGM on September 22, 2026, via video conference
  • Agenda includes adopting FY26 financials and reappointing CEO N. K. Menon
  • Vijaya Mani is up for appointment as a Non-Executive, Non-Independent Director
  • Remote e-voting runs from September 19 to September 21, 2026
  • Book closure period is from September 15 to September 22, 2026
powered bylight_fuzz_icon
48763927

*this image is generated using AI for illustrative purposes only.

Colinz Laboratories has scheduled its 40th Annual General Meeting (AGM) for Tuesday, September 22, 2026, at 2:30 pm. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (OAVM), with the company’s registered office in Mumbai deemed as the venue.

The primary business items include the adoption of the audited financial statements for the fiscal year ended March 31, 2026, and the reappointment of Mr. N. K. Menon as Whole-Time Director and Chief Executive Officer. Shareholders will also vote on the appointment of Mrs. Vijaya Mani as a Non-Executive, Non-Independent Director.

Key Agenda Items

The AGM notice outlines several ordinary and special resolutions for shareholder approval:

  • Adoption of Financials: Consideration and adoption of the audited balance sheet, statement of profit and loss, and cash flow statement for FY26, along with the reports of the Board of Directors and Independent Auditors.
  • Director Reappointment: Reappointment of Mr. N. K. Menon (DIN: 01111297), who retires by rotation. He will serve as Whole-Time Director and CEO for one year from October 1, 2026, to September 30, 2027.
  • New Director Appointment: Appointment of Mrs. Vijaya Mani (DIN: 11363910) as a Director (Promoter, Non-Executive). She was initially appointed as an Additional Director on November 11, 2025.

Remuneration Details

Mr. N. K. Menon’s reappointment requires a special resolution due to his age exceeding 70 years. His remuneration package for the upcoming tenure is structured as follows:

Component Amount (₹ Lacs p.a.)
Salary Range 7.5 to 12.50
Allowances & Perquisites 7.50

The package includes statutory benefits such as gratuity, insurance premiums, and medical claims. House rent allowance is capped at 50% of the basic salary. Mr. Menon will not receive sitting fees for board or committee meetings.

Voting and Record Dates

The register of members and share transfer books will remain closed from September 15, 2026, to September 22, 2026, both days inclusive. The cut-off date for determining eligibility for remote e-voting is September 15, 2026.

Remote e-voting will be available from 9:00 am on September 19, 2026, to 5:00 pm on September 21, 2026. Members who have not voted remotely can cast their votes electronically during the AGM. Ms. Ashwini Vaze, Practising Company Secretary, has been appointed as the scrutinizer for the e-voting process.

Notice Dispatch and Publication

In compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the company dispatched the AGM notice and the Annual Report for FY26 electronically on August 21, 2026. The notice was also published in newspapers, including Free Press Journal and Nav Shakti, on August 27, 2026.

Members who have not registered their email addresses are advised to do so with their Depository Participants or the Registrar and Transfer Agent, Bigshare Services. The notice is also available on the company’s website and the BSE website.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.01%+4.15%-13.07%+72.74%+68.41%+320.29%

How might the reappointment of CEO Mr. N. K. Menon, who is over 70, influence investor confidence regarding long-term leadership stability and succession planning?

What strategic initiatives is Colinz Laboratories expected to prioritize in FY27 to justify the proposed remuneration package for its Whole-Time Director?

How will the appointment of Mrs. Vijaya Mani as a Non-Executive Director impact the company's corporate governance structure and board dynamics?

More News on Colinz Laboratories

1 Year Returns:+68.41%